William Blair Issues Optimistic Estimate for CRDF Earnings

Key Points

• William Blair has revised its Q3 2025 earnings estimate for Cardiff Oncology to ($0.19) per share, an improvement from the previous estimate of ($0.25), maintaining an "Outperform" rating for the stock.
• Cardiff Oncology reported Q2 earnings of ($0.21) EPS, falling short of the consensus estimate of ($0.19), but beating revenue expectations with $0.12 million compared to $0.11 million.
• Insider Director Gary W. Pace purchased 15,000 shares at $2.45 each, increasing his ownership stake in the company, which now stands at approximately 1.13% of the total shares.

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Stock analysts at William Blair lifted their Q3 2025 EPS estimates for Cardiff Oncology in a report released on Wednesday, July 30th. William Blair analyst A. Hsieh now expects that the company will post earnings per share of ($0.19) for the quarter, up from their previous forecast of ($0.25). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Cardiff Oncology's current full-year earnings is ($0.99) per share. William Blair also issued estimates for Cardiff Oncology's Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.78) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.65) EPS and FY2027 earnings at ($0.73) EPS.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.11 million.

CRDF has been the subject of a number of other reports. LADENBURG THALM/SH SH started coverage on shares of Cardiff Oncology in a research report on Tuesday, July 8th. They issued a "buy" rating and a $19.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Cardiff Oncology in a research report on Tuesday, June 24th. They issued a "hold" rating and a $3.50 price objective for the company. Finally, HC Wainwright lifted their target price on shares of Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $11.70.

Cardiff Oncology Trading Up 2.6%

Shares of CRDF stock traded up $0.07 during trading hours on Friday, reaching $2.58. The stock had a trading volume of 1,175,164 shares, compared to its average volume of 1,445,786. The stock's fifty day simple moving average is $3.58 and its 200 day simple moving average is $3.49. Cardiff Oncology has a 12 month low of $2.06 and a 12 month high of $5.64. The firm has a market capitalization of $171.31 million, a PE ratio of -2.95 and a beta of 1.54.

Institutional Investors Weigh In On Cardiff Oncology

A number of hedge funds have recently made changes to their positions in CRDF. SteelPeak Wealth LLC raised its holdings in Cardiff Oncology by 23.2% during the 2nd quarter. SteelPeak Wealth LLC now owns 22,800 shares of the company's stock valued at $72,000 after buying an additional 4,300 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Cardiff Oncology during the 4th quarter valued at $25,000. Thoroughbred Financial Services LLC increased its position in Cardiff Oncology by 43.8% during the 4th quarter. Thoroughbred Financial Services LLC now owns 19,614 shares of the company's stock valued at $85,000 after purchasing an additional 5,970 shares during the period. American Century Companies Inc. increased its position in Cardiff Oncology by 12.8% during the 4th quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock valued at $234,000 after purchasing an additional 6,140 shares during the period. Finally, Corebridge Financial Inc. increased its position in Cardiff Oncology by 40.8% during the 1st quarter. Corebridge Financial Inc. now owns 28,555 shares of the company's stock valued at $90,000 after purchasing an additional 8,277 shares during the period. 16.29% of the stock is currently owned by institutional investors.

Insider Transactions at Cardiff Oncology

In related news, Director Gary W. Pace bought 15,000 shares of the company's stock in a transaction on Wednesday, July 30th. The stock was acquired at an average cost of $2.45 per share, for a total transaction of $36,750.00. Following the completion of the transaction, the director directly owned 1,345,676 shares in the company, valued at $3,296,906.20. This trade represents a 1.13% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.70% of the stock is currently owned by insiders.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.